US-based healthcare software-as-a-service (SaaS) company Glytec has entered a partnership with MUSC Health to improve diabetes and glycaemic management across the latter’s hospital network.
This move aims to enhance patient safety and clinical results.
Go deeper with GlobalData
The partnership comes at a crucial time, with more than 37 million Americans diagnosed with diabetes and a substantial number at risk of developing it.
Glytec’s technology represents a step forward in managing this prevalent condition, especially as more than one-third of hospitalised patients need insulin therapy.
The urgency for such solutions is highlighted by new hospital glycemia reporting mandates from the Centers for Medicare and Medicaid Services (CMS).
MUSC Health’s leadership and IT experts reviewed various diabetes and insulin management solutions before the selection of Glytec.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company’s platform was chosen for its compatibility with MUSC’s existing electronic medical record (EMR) system EPIC.
Glytec’s software is set to provide support in making clinical decisions, decreasing glycaemic management variability, and streamlining insulin therapy.
MUSC Health chief quality officer Danielle Scheurer said: “Our collaboration with Glytec marks a significant milestone in our ongoing efforts to enhance diabetes care across MUSC.
“By integrating Glytec’s insulin management system with our EMR, we can ensure a more effective, data-driven approach to managing inpatient and outpatient diabetes care, improving workflows for our clinical teams and delivering better results for our patients.”
The partnership will also prepare MUSC Health’s hospitals to meet the new CMS requirements, using Glytec’s FDA-cleared software across all clinical settings.
Glytec CEO Patrick Cua said: “Our software will help MUSC clinicians provide personalised, cost-effective care to a meaningful percentage of patients, providing them and their families with access to the leading platform in diabetes safety and outcomes.”
Last year, Glytec had partnered with the Leapfrog Group, a healthcare non-profit, through its Partner Advisory Committee (PAC).
